Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Patient Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+15.3%
YTD+42%
Annualized+0.076%
Positioning StanceCONSTRUCTIVE
Market CapAll Cap
Digest Analysis
Quick Take
"Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Cap Value while maintaining core holdings in Megacap AI leaders."
Executive Summary
In the 2Q25 letter, Samantha McLemore highlights the fund's strong quarterly return of 15.3% net of fees, outperforming the S&P 500's 10.9%. Despite early Q3 indicators of market frothiness and renewed tariff risks, she emphasizes that the underlying economy remains resilient. McLemore outlines her contrarian philosophy, drawing on personal experiences to stress the importance of discipline and delayed gratification. The portfolio is structurally bar-belled: 21.6% is allocated to secular AI leaders (Mag 7), while the remainder is heavily focused on highly discounted areas. Specifically, Healthcare and Small Cap Value represent roughly half the portfolio (46.2%). Key actions during the quarter included buying Norwegian Cruise Lines (NCLH) and UnitedHealth Group (UNH) during temporary market pullbacks.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
80%
Market Conviction
High-conviction positioning: Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
85%
Growth Outlook
Market outlook remains above average conviction: Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
85%
Risk Appetite
Risk appetite posture is above average conviction: Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
80%
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
80%
Forward Guidance
Forward guidance signal: Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
85%
Language Signal
Tone analysis indicates above average conviction language: Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
50%
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
80%
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...
80%
Time Horizon
Investment time horizon reflects a high conviction orientation. Opportunity Equity Strategy delivered a robust 15.3% net return in Q2 2025, using short-term market panic to increase exposure to deeply discounted names in Healthcare and Small Ca...